Data / Form D filings / Metsera, Inc.
Metsera, Inc.: Form D filing
Metsera, Inc., a biotechnology company in New York, NY, filed a Form D with the SEC in 2024. The latest, on November 20, 2024, reports $215 million sold of a $215 million offering to 38 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3 World Trade Center, 175 Greenwich Street, New York, NY, 10007
- Phone
- (212) 784-6595
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2040807
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 20, 2024 | New notice | $214,999,939 | $214,999,939 | 38 | Nov 12, 2024 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kristina L. Burow | Director | |
| Christopher J. Visioli | Executive Officer | |
| Brian J. Hubbard | Executive Officer | |
| Christopher Whitten Bernard | Executive Officer, Director | |
| Steven J. Marso | Executive Officer | |
| Clive A. Meanwell | Director | |
| Paul L. Berns | Director | |
| Joshua L. Pinto | Director |
Other biotechnology companies in New York that filed recently
- Swep Bio, Inc. $2.5 million · Oct 29, 2026
- Hypercell Technologies Inc. $3 million · Oct 14, 2026
- CAD Therapeutics, Inc. $4 million · Oct 2, 2026
- Vicora, Inc. $2.3 million · Sep 18, 2026
- GevRx Nutraceuticals, Inc. $300,000 · Sep 18, 2026
- Episteme Prognostics, Inc. $5.1 million · Sep 4, 2026
Every Form D from the week of Nov 18, 2024 · All recent filings in New York · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Metsera, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.